| Schedule of segment reporting |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
March 31, |
| |
|
2026 |
|
2025 |
|
2024 |
| |
|
Digital & Compute |
|
Immuno-Oncology |
|
Immuno-Oncology |
|
Immuno-Oncology |
| |
|
|
|
|
|
|
|
|
| Segment revenues |
|
$ |
97 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
|
— |
|
|
|
2,801 |
|
|
|
3,129 |
|
|
|
12,535 |
|
| General and administrative expenses |
|
|
16,344 |
|
|
|
3,855 |
|
|
|
4,254 |
|
|
|
5,664 |
|
| Depreciation and amortization expense |
|
|
193 |
|
|
|
— |
|
|
|
35 |
|
|
|
54 |
|
| Segment loss from operations |
|
|
(16,440 |
) |
|
|
(6,656 |
) |
|
|
(7,418 |
) |
|
|
(18,253 |
) |
| Change in fair value of warrant liability |
|
|
1,097 |
|
|
|
1,786 |
|
|
|
(388 |
) |
|
|
6,868 |
|
| Change in fair value of deferred purchase price payable - Tarus and deferred
obligation - iOx milestone |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,305 |
|
| Change in fair value of put rights, net of redemptions |
|
|
(5,959 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Loss on revaluation of digital assets |
|
|
(1,411 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Loss on revaluation of digital asset receivables |
|
|
(2,349 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Realized loss on sale of digital assets |
|
|
(1,700 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Realized loss on novation of digital asset receivables |
|
|
676 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Gain on settlement with Parexel - iOx CRO |
|
|
— |
|
|
|
— |
|
|
|
946 |
|
|
|
— |
|
| Loss on Registered Direct Offering |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,432 |
) |
| Offering costs |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(662 |
) |
| Impairment loss - iOx IPR&D |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(57,890 |
) |
| Impairment loss - Tarus IPR&D |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(23,615 |
) |
| Impairment loss - Stimunity |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,002 |
) |
| Impairment loss - Saugatuck |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(178 |
) |
| Commitment fee under Committed Purchase Agreement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(839 |
) |
| Gain on dissolution of investment in associate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
27 |
|
| Gain from sale of investment in public company |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
725 |
|
| Impairment loss - investment in Compedica |
|
|
— |
|
|
|
(4,804 |
) |
|
|
— |
|
|
|
— |
|
| Loss on revaluation of investment in Compedica |
|
|
(182 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Change in fair value of TON payable to settle put rights exercised |
|
|
51 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Gain on settlement of TON payable |
|
|
336 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Loss on settlement of put right liability |
|
|
(916 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Foreign exchange transaction (loss) gain |
|
|
4 |
|
|
|
(5 |
) |
|
|
(7 |
) |
|
|
7 |
|
| Interest (expense) income, net |
|
|
(1,022 |
) |
|
|
8 |
|
|
|
86 |
|
|
|
242 |
|
| Loss on extinguishment of debt |
|
|
(582 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
| Gain on forgiveness of loan interest |
|
$ |
837 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| Share of losses from equity method investment |
|
|
— |
|
|
|
(44 |
) |
|
|
— |
|
|
|
(233 |
) |
| Segment loss before benefit for income taxes |
|
|
(28,912 |
) |
|
|
(9,715 |
) |
|
|
(6,781 |
) |
|
|
(85,930 |
) |
| Income tax benefit |
|
|
— |
|
|
|
— |
|
|
|
3 |
|
|
|
10,548 |
|
| Segment net loss |
|
$ |
(28,912 |
) |
|
$ |
(9,715 |
) |
|
$ |
(6,778 |
) |
|
$ |
(75,382 |
) |